相似文献
1
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021.
Virol J. 2021 Aug 14;18(1):168. doi: 10.1186/s12985-021-01638-5.
2
A doubt of multiple introduction of SARS-CoV-2 in Italy: A preliminary overview.
J Med Virol. 2020 Sep;92(9):1634-1636. doi: 10.1002/jmv.25773. Epub 2020 Mar 27.
3
Novel SARS-CoV-2 Variants in Italy: The Role of Veterinary Public Health Institutes.
Viruses. 2021 Mar 25;13(4):549. doi: 10.3390/v13040549.
4
Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.
Clin Microbiol Infect. 2021 Aug;27(8):1174.e1-1174.e4. doi: 10.1016/j.cmi.2021.05.007. Epub 2021 May 10.
5
Self-collection and pooling of samples as resources-saving strategies for RT-PCR-based SARS-CoV-2 surveillance, the example of travelers in French Polynesia.
PLoS One. 2021 Sep 2;16(9):e0256877. doi: 10.1371/journal.pone.0256877. eCollection 2021.
6
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy.
Nat Commun. 2021 Jan 19;12(1):434. doi: 10.1038/s41467-020-20688-x.
7
A Founder Effect Led Early SARS-CoV-2 Transmission in Spain.
J Virol. 2021 Jan 13;95(3). doi: 10.1128/JVI.01583-20.
8
SARS-CoV-2 AY.4.2 variant circulating in Italy: Genomic preliminary insight.
J Med Virol. 2022 Apr;94(4):1689-1692. doi: 10.1002/jmv.27451. Epub 2021 Nov 17.
9
A straightforward molecular strategy to retrospectively investigate the spread of SARS-CoV-2 VOC202012/01 B.1.1.7 variant.
J Infect Dev Ctries. 2021 Mar 7;15(2):242-246. doi: 10.3855/jidc.14972.
10
SARS-CoV-2 Variants in Rhode Island.
R I Med J (2013). 2021 Sep 1;104(7):16-20.
引用本文的文献
1
Suspected intracranial hypertension in COVID-19 patients with severe respiratory failure.
PLoS One. 2024 Sep 19;19(9):e0310077. doi: 10.1371/journal.pone.0310077. eCollection 2024.
2
Covid-19 Occupational Risk Incidence and Working Sectors Involved During the Pandemic in Italy.
Saf Health Work. 2023 Dec;14(4):398-405. doi: 10.1016/j.shaw.2023.10.011. Epub 2023 Oct 26.
3
Extracellular vesicle features are associated with COVID-19 severity.
J Cell Mol Med. 2023 Dec;27(24):4107-4117. doi: 10.1111/jcmm.17996. Epub 2023 Nov 15.
4
Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study.
Infect Dis Ther. 2023 Oct;12(10):2437-2456. doi: 10.1007/s40121-023-00871-5. Epub 2023 Oct 5.
5
Clinical efficacy of the first two doses of anti-SARS-CoV-2 mRNA vaccines in solid cancer patients.
Cancer Med. 2023 Jun;12(12):12967-12974. doi: 10.1002/cam4.5968. Epub 2023 Apr 28.
6
Alterations in the Expression of IFN Lambda, IFN Gamma and Toll-like Receptors in Severe COVID-19 Patients.
Microorganisms. 2023 Mar 8;11(3):689. doi: 10.3390/microorganisms11030689.
7
Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes.
Viruses. 2023 Feb 3;15(2):428. doi: 10.3390/v15020428.
8
Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience.
Microorganisms. 2023 Jan 25;11(2):312. doi: 10.3390/microorganisms11020312.
9
Negative predictive value of the FebriDx host response point-of-care test in patients presenting to a single Australian emergency department with suspected COVID-19: an observational diagnostic accuracy study.
BMJ Open. 2022 Dec 29;12(12):e065568. doi: 10.1136/bmjopen-2022-065568.
10
Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April-December 2021 in Italy.
Viruses. 2022 Nov 12;14(11):2508. doi: 10.3390/v14112508.
本文引用的文献
1
Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy.
Viruses. 2021 Apr 29;13(5):794. doi: 10.3390/v13050794.
2
Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.
Euro Surveill. 2021 Apr;26(16). doi: 10.2807/1560-7917.ES.2021.26.16.2100348.
3
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.
Science. 2021 May 21;372(6544):815-821. doi: 10.1126/science.abh2644. Epub 2021 Apr 14.
4
The first familial cluster of the B.1.1.7 variant of SARS-CoV-2 in the northeast of Italy.
Infection. 2021 Dec;49(6):1341-1345. doi: 10.1007/s15010-021-01609-6. Epub 2021 Apr 10.
5
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.
Nature. 2021 May;593(7858):266-269. doi: 10.1038/s41586-021-03470-x. Epub 2021 Mar 25.
6
Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February.
Euro Surveill. 2021 Mar;26(11). doi: 10.2807/1560-7917.ES.2021.26.11.2100256.
7
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.
Nature. 2021 May;593(7858):270-274. doi: 10.1038/s41586-021-03426-1. Epub 2021 Mar 15.
8
Detection of a SARS-CoV-2 variant of concern in South Africa.
Nature. 2021 Apr;592(7854):438-443. doi: 10.1038/s41586-021-03402-9. Epub 2021 Mar 9.
9
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study.
BMJ. 2021 Mar 9;372:n579. doi: 10.1136/bmj.n579.
10
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
Science. 2021 Apr 9;372(6538). doi: 10.1126/science.abg3055. Epub 2021 Mar 3.
Zotero 插件